PE20141149A1 - Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) - Google Patents

Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)

Info

Publication number
PE20141149A1
PE20141149A1 PE2013002137A PE2013002137A PE20141149A1 PE 20141149 A1 PE20141149 A1 PE 20141149A1 PE 2013002137 A PE2013002137 A PE 2013002137A PE 2013002137 A PE2013002137 A PE 2013002137A PE 20141149 A1 PE20141149 A1 PE 20141149A1
Authority
PE
Peru
Prior art keywords
tissue factor
tfpi
monoclonal antibodies
antibodies against
path inhibitor
Prior art date
Application number
PE2013002137A
Other languages
English (en)
Spanish (es)
Inventor
Zhuozhi Wang
John Murphy
Tobias Marquardt
Dieter Moosmayer
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46932389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141149(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of PE20141149A1 publication Critical patent/PE20141149A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2013002137A 2011-04-01 2012-03-30 Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) PE20141149A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161471101P 2011-04-01 2011-04-01

Publications (1)

Publication Number Publication Date
PE20141149A1 true PE20141149A1 (es) 2014-08-28

Family

ID=46932389

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002137A PE20141149A1 (es) 2011-04-01 2012-03-30 Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)

Country Status (37)

Country Link
US (5) US20140294832A1 (cg-RX-API-DMAC7.html)
EP (1) EP2694544B1 (cg-RX-API-DMAC7.html)
JP (4) JP6170903B2 (cg-RX-API-DMAC7.html)
KR (2) KR101995302B1 (cg-RX-API-DMAC7.html)
CN (2) CN107090046A (cg-RX-API-DMAC7.html)
AU (3) AU2012236296A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013025376A2 (cg-RX-API-DMAC7.html)
CA (2) CA2831907C (cg-RX-API-DMAC7.html)
CL (1) CL2013002811A1 (cg-RX-API-DMAC7.html)
CO (1) CO6890074A2 (cg-RX-API-DMAC7.html)
CR (1) CR20130499A (cg-RX-API-DMAC7.html)
CU (1) CU20130128A7 (cg-RX-API-DMAC7.html)
CY (1) CY1121538T1 (cg-RX-API-DMAC7.html)
DK (1) DK2694544T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2013000218A (cg-RX-API-DMAC7.html)
EA (2) EA201991704A3 (cg-RX-API-DMAC7.html)
EC (1) ECSP13012913A (cg-RX-API-DMAC7.html)
ES (1) ES2722824T3 (cg-RX-API-DMAC7.html)
GT (1) GT201300229A (cg-RX-API-DMAC7.html)
HK (1) HK1243426A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20190467T1 (cg-RX-API-DMAC7.html)
HU (1) HUE042706T2 (cg-RX-API-DMAC7.html)
IL (4) IL228633B (cg-RX-API-DMAC7.html)
LT (1) LT2694544T (cg-RX-API-DMAC7.html)
MX (1) MX2013011218A (cg-RX-API-DMAC7.html)
MY (2) MY165499A (cg-RX-API-DMAC7.html)
PE (1) PE20141149A1 (cg-RX-API-DMAC7.html)
PH (4) PH12013502039B1 (cg-RX-API-DMAC7.html)
PL (1) PL2694544T3 (cg-RX-API-DMAC7.html)
PT (1) PT2694544T (cg-RX-API-DMAC7.html)
RS (1) RS58633B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201602606UA (cg-RX-API-DMAC7.html)
SI (1) SI2694544T1 (cg-RX-API-DMAC7.html)
TR (1) TR201905101T4 (cg-RX-API-DMAC7.html)
UA (1) UA113623C2 (cg-RX-API-DMAC7.html)
WO (1) WO2012135671A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201308169B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104984319B (zh) 2008-12-19 2025-05-09 武田药品工业株式会社 Tfpi抑制剂和使用方法
ES2458665T5 (es) † 2008-12-22 2021-06-30 Novo Nordisk As Anticuerpos contra el inhibidor de la vía del factor tisular
HUE047173T2 (hu) 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
EP3146977B1 (en) 2010-03-19 2024-05-08 Takeda Pharmaceutical Company Limited Tfpi inhibitors and methods of use
EA201991704A3 (ru) * 2011-04-01 2020-06-30 Байер Хелфкеа Ллк Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
KR102263685B1 (ko) 2012-03-21 2021-06-11 다케다 야쿠힌 고교 가부시키가이샤 Tfpi 저해제 및 사용 방법
KR20150030639A (ko) * 2012-03-30 2015-03-20 바이엘 헬스케어 엘엘씨 프로테아제로 조절된 항체
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
ES2926773T3 (es) * 2013-03-15 2022-10-28 Novo Nordisk As Anticuerpos capaces de unirse específicamente a dos epítopos en el inhibidor de la ruta del factor tisular
SI2970497T1 (en) 2013-03-15 2018-04-30 Bayer Healthcare Llc Variants of anti-TFPI antibodies with differential binding over the pH range for improved pharmacokinetic properties
JP6584397B2 (ja) * 2013-07-19 2019-10-02 ノヴォ ノルディスク アー／エス 凝血促進活性を誘発することができる組織因子経路インヒビターのｎ末端部分を認識する抗体
ES2905085T3 (es) * 2014-09-17 2022-04-07 Novo Nordisk As Anticuerpos que pueden unirse a dos epítopos en el inhibidor de la vía del factor tisular (1-161)
CA2977621C (en) * 2015-02-25 2021-11-23 Mogam Institute For Biomedical Research Antibody binding to tfpi and composition comprising the same
SG10201912817YA (en) * 2015-08-19 2020-02-27 Pfizer Tissue factor pathway inhibitor antibodies and uses thereof
CN112424593A (zh) * 2018-07-25 2021-02-26 索尼公司 凝血系统分析装置
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06153985A (ja) * 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
ES2458665T5 (es) * 2008-12-22 2021-06-30 Novo Nordisk As Anticuerpos contra el inhibidor de la vía del factor tisular
HUE047173T2 (hu) * 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
EA201991704A3 (ru) * 2011-04-01 2020-06-30 Байер Хелфкеа Ллк Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations

Also Published As

Publication number Publication date
CR20130499A (es) 2013-10-24
MX2013011218A (es) 2013-10-17
ECSP13012913A (es) 2014-02-28
TR201905101T4 (tr) 2019-05-21
IL274686A (en) 2020-06-30
CN103797030A (zh) 2014-05-14
WO2012135671A2 (en) 2012-10-04
IL274686B (en) 2021-09-30
PH12019500439A1 (en) 2020-10-12
IL257145A (en) 2018-03-29
CA2831907C (en) 2020-03-24
AU2019201814A1 (en) 2019-04-04
RS58633B1 (sr) 2019-05-31
PL2694544T3 (pl) 2019-07-31
CN107090046A (zh) 2017-08-25
CA2831907A1 (en) 2012-10-04
ZA201308169B (en) 2016-03-30
PT2694544T (pt) 2019-04-02
EP2694544A4 (en) 2015-03-25
HRP20190467T1 (hr) 2019-05-03
SG193594A1 (en) 2013-10-30
US20190194353A1 (en) 2019-06-27
PH12019500441A1 (en) 2020-10-12
DK2694544T3 (en) 2019-04-15
KR101995302B1 (ko) 2019-07-02
MY165499A (en) 2018-03-27
ES2722824T3 (es) 2019-08-19
HUE042706T2 (hu) 2019-07-29
PH12013502039A1 (en) 2013-12-16
EA201991704A3 (ru) 2020-06-30
JP2018172411A (ja) 2018-11-08
WO2012135671A3 (en) 2012-12-13
AU2012236296A1 (en) 2013-10-24
UA113623C2 (uk) 2017-02-27
CU20130128A7 (es) 2014-03-26
IL228633B (en) 2018-03-29
IL283829A (en) 2021-07-29
AU2017203105A1 (en) 2017-06-01
EA034214B1 (ru) 2020-01-17
LT2694544T (lt) 2019-04-25
CN103797030B (zh) 2017-05-31
CO6890074A2 (es) 2014-03-10
JP2014511685A (ja) 2014-05-19
KR20140019428A (ko) 2014-02-14
DOP2013000218A (es) 2013-11-15
EA201991704A2 (ru) 2020-03-31
US20170107298A1 (en) 2017-04-20
NZ615969A (en) 2016-01-29
KR20190079698A (ko) 2019-07-05
CL2013002811A1 (es) 2014-02-28
GT201300229A (es) 2014-11-13
EP2694544A2 (en) 2014-02-12
JP6170903B2 (ja) 2017-07-26
US20220041752A1 (en) 2022-02-10
EP2694544B1 (en) 2019-01-23
CY1121538T1 (el) 2020-05-29
JP2017113019A (ja) 2017-06-29
EA201301107A1 (ru) 2014-11-28
BR112013025376A2 (pt) 2017-07-25
MY190951A (en) 2022-05-24
PH12019500440A1 (en) 2020-10-12
PH12013502039B1 (en) 2013-12-16
US20140294832A1 (en) 2014-10-02
SI2694544T1 (sl) 2019-06-28
SG10201602606UA (en) 2016-04-28
JP2021019619A (ja) 2021-02-18
CA3068997A1 (en) 2012-10-04
JP6363747B2 (ja) 2018-07-25
US20180194857A1 (en) 2018-07-12
HK1243426A1 (zh) 2018-07-13
IL228633A0 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
PE20141149A1 (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
CL2019002056A1 (es) Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650)
CL2022000328A1 (es) Anticuerpo humanizado que se une específicamente al receptor de transferrina humano (tfr); composición farmacéutica; uso del anticuerpo humanizado para preparar un medicamento útil para tratar un trastorno neurológico. (divisional solicitud no. 3207-2017)
EA201791168A1 (ru) Способы и составы для лечения сосудистых заболеваний глаз
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
PE20190907A1 (es) Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
ECSP19025350A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
EP2582722A4 (en) ANTIBODIES AGAINST GD2
AR080026A1 (es) Metodos de tratamiento de enfermedades autoinmunitarias con antagonistas del ligando 4 similar a delta (dll4)
MX2018008658A (es) Composiciones y metodos para inhibir masp-1 y/o masp-2 y/ o masp-3 para el tratamiento de la hemoglobinuria paroxistica nocturna.
UY34116A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
PE20250415A1 (es) Composiciones y metodos de inhibicion del masp-3 para el tratamiento de diversas enfermedades y trastornos
EA201491644A1 (ru) Фармацевтические композиции
EA201690159A1 (ru) Способы и композиции для лечения рака
AR099698A1 (es) Anticuerpos contra el c5 que tienen farmacocinética mejorada
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
CO6390041A2 (es) Agentes y antagonistas fijaodres de notch y metodos para el uso de los mismos.
ECSP10010372A (es) Métodos y composiciones que utilizan polipéptidos de fusión de klotho-fgf
MX2023007840A (es) Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
AR079572A1 (es) Anticuerpos que se enlazan a los epitopos de un polipeptido wise
AR102595A1 (es) Anticuerpos anti-ang2 y métodos de utilización
CO6950477A2 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
EE05760B1 (et) Ravimkoostis
PE20190171A1 (es) Anticuerpos de union a trombina y usos del mismo
CY1124280T1 (el) Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap

Legal Events

Date Code Title Description
FG Grant, registration